Jaguar Health, Inc. (JAGX)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 15M 30M 45M Q4 '16: 141.5K Q1 '17: 925.8K Q2 '17: 1.8M Q3 '17: 2.8M Q4 '17: 4.4M Q1 '18: 4.3M Q2 '18: 4.3M Q3 '18: 4.4M Q4 '18: 4.4M Q1 '19: 5.2M Q2 '19: 6M Q3 '19: 5.9M Q4 '19: 5.8M Q1 '20: 5.1M Q2 '20: 6.5M Q3 '20: 8.3M Q4 '20: 9.4M Q2 '24: 10.2M Q3 '24: 10.5M Q4 '24: 11.7M Q1 '25: 11.6M Q2 '25: 11.8M Q3 '25: 11.8M Q4 '25: 11.5M Q1 '26: 29.6M Q2 '26: 27.8M Q1 '17 Q1 '18 Q1 '19 Q1 '20 Q2 '24 Q2 '25 Q2 '26

Gross Profit TTM

0 9M 18M 27M Q4 '16: 89.6K Q1 '17: 876K Q2 '17: 1.7M Q3 '17: 2.6M Q4 '17: 3.5M Q1 '18: 3M Q2 '18: 2.4M Q3 '18: 1.9M Q4 '18: 1.7M Q1 '19: 2M Q2 '19: 2.2M Q3 '19: 1.8M Q4 '19: 2M Q1 '20: 1.4M Q2 '20: 3.1M Q3 '20: 5.1M Q4 '20: 6.1M Q2 '24: 8.1M Q3 '24: 8.4M Q4 '24: 9.7M Q1 '25: 9.5M Q2 '25: 9.7M Q3 '25: 9.7M Q4 '25: 7.7M Q1 '26: 25.2M Q2 '26: 22.9M Q1 '17 Q1 '18 Q1 '19 Q1 '20 Q2 '24 Q2 '25 Q2 '26

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income TTM

-60M -40M -20M 0 20M 40M 60M Q3 '16: -14.1M Q4 '16: -13.6M Q1 '17: -13.8M Q2 '17: -12.7M Q3 '17: -16.9M Q4 '17: -34.2M Q1 '18: -35.5M Q2 '18: -40.2M Q3 '18: -39.4M Q4 '18: -30.8M Q1 '19: -31.5M Q2 '19: -35M Q3 '19: -35.2M Q4 '19: -28.9M Q1 '20: -30.8M Q2 '20: -28.7M Q3 '20: -27.3M Q4 '20: -26.6M Q1 '21: -27.8M Q2 '21: -30.9M Q3 '21: -35M Q4 '21: -40.7M Q1 '22: -43.7M Q2 '22: -38.6M Q3 '22: -39M Q4 '22: -34.4M Q1 '23: -32.5M Q2 '23: -34.1M Q3 '23: -33M Q4 '23: -34.3M Q1 '24: -32.7M Q2 '24: -31.8M Q3 '24: -30.2M Q4 '24: -30.8M Q1 '25: -32M Q2 '25: -32.8M Q3 '25: -32.8M Q4 '25: -45.9M Q1 '26: -26.3M Q2 '26: -25.9M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Net Income TTM

-60M -40M -20M 0 20M 40M 60M Q3 '16: -15.2M Q4 '16: -14.7M Q1 '17: -15.5M Q2 '17: -13.6M Q3 '17: -5.4M Q4 '17: -22M Q1 '18: -22.9M Q2 '18: -28.8M Q3 '18: -39.7M Q4 '18: -32.1M Q1 '19: -34.8M Q2 '19: -43.8M Q3 '19: -45.2M Q4 '19: -38.5M Q1 '20: -38.2M Q2 '20: -30.7M Q3 '20: -31M Q4 '20: -33.8M Q1 '21: -37.9M Q2 '21: -42.7M Q3 '21: -47.1M Q4 '21: -52.6M Q1 '22: -58.6M Q2 '22: -53.9M Q3 '22: -54.2M Q4 '22: -48.1M Q1 '23: -42.3M Q2 '23: -45.1M Q3 '23: -40.4M Q4 '23: -41.4M Q1 '24: -38.5M Q2 '24: -35.8M Q3 '24: -37.9M Q4 '24: -38.5M Q1 '25: -39.7M Q2 '25: -40.6M Q3 '25: -40.3M Q4 '25: -53.6M Q1 '26: -34.4M Q2 '26: -36.8M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Cost of Revenue TTM

0 2M 4M 6M Q3 '16: 72.4K Q4 '16: 52K Q1 '17: 49.7K Q2 '17: 65.9K Q3 '17: 262.2K Q4 '17: 880.4K Q1 '18: 1.3M Q2 '18: 1.9M Q3 '18: 2.4M Q4 '18: 2.8M Q1 '19: 3.2M Q2 '19: 3.8M Q3 '19: 4M Q4 '19: 3.8M Q1 '20: 3.6M Q2 '20: 3.4M Q3 '20: 3.2M Q4 '20: 3.3M Q1 '21: 3.2M Q2 '21: 2.8M Q3 '21: 2.7M Q4 '21: 2.3M Q1 '22: 2.2M Q2 '22: 2M Q3 '22: 2M Q4 '22: 2M Q1 '23: 1.9M Q2 '23: 1.9M Q3 '23: 1.8M Q4 '23: 2M Q1 '24: 2.1M Q2 '24: 2.1M Q3 '24: 2.1M Q4 '24: 2M Q1 '25: 2M Q2 '25: 2.1M Q3 '25: 2.1M Q4 '25: 3.8M Q1 '26: 4.4M Q2 '26: 4.9M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Operating Cash Flow TTM

-45M -30M -15M 0 15M 30M 45M Q3 '16: -15.6M Q4 '16: -14.4M Q1 '17: -10.2M Q2 '17: -7.6M Q3 '17: -7.2M Q4 '17: -9.8M Q1 '18: -19.2M Q2 '18: -23.4M Q3 '18: -23.2M Q4 '18: -22.7M Q1 '19: -16.6M Q2 '19: -16.5M Q3 '19: -22.2M Q4 '19: -20.5M Q1 '20: -21.3M Q2 '20: -20M Q3 '20: -14.4M Q4 '20: -15.3M Q1 '21: -17.7M Q2 '21: -23.6M Q3 '21: -30.1M Q4 '21: -35M Q1 '22: -36M Q2 '22: -36.5M Q3 '22: -35.6M Q4 '22: -33.1M Q1 '23: -35.4M Q2 '23: -34M Q3 '23: -32.2M Q4 '23: -33.2M Q1 '24: -30.3M Q2 '24: -29.5M Q3 '24: -29M Q4 '24: -29.4M Q1 '25: -29.7M Q2 '25: -27.7M Q3 '25: -26M Q4 '25: -23.7M Q1 '26: -7.5M Q2 '26: -6.7M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Free Cash Flow TTM

-45M -30M -15M 0 15M 30M 45M Q3 '16: -15.7M Q4 '16: -14.5M Q4 '18: -22.7M Q4 '20: -15.3M Q2 '23: -34M Q3 '23: -32.2M Q3 '16 Q4 '16 Q4 '18 Q4 '20 Q2 '23 Q3 '23

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 50M 100M 150M Q3 '16: 11.3M Q1 '17: 14.2M Q3 '17: 4.5M Q1 '18: 129.5M Q3 '18: 12.1M Q2 '20: 23.9M Q3 '20: 13.4M Q1 '21: 42.6M Q2 '21: 45M Q3 '21: 45.8M Q1 '22: 778.5K Q2 '22: 1.1M Q3 '22: 1.4M Q1 '23: 5.1M Q2 '23: 293.9K Q3 '23: 345.7K Q1 '24: 105.9K Q2 '24: 3.6M Q3 '24: 374.8K Q1 '25: 17.9K Q2 '25: 29K Q3 '25: 1.5M Q1 '26: 515.8K Q2 '26: 809.1K Q3 '17 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-3000.00 -2000.00 -1000.00 0.00 1000.00 2000.00 3000.00 Q2 '15: -4.19 Q3 '15: -3.54 Q4 '15: -3.21 Q1 '16: -2.21 Q2 '16: -1.56 Q3 '16: -1.50 Q4 '16: -1.36 Q1 '17: -1.26 Q2 '17: -2.75 Q3 '17: -1.34 Q1 '19: -80.61 Q2 '19: -42.48 Q3 '19: -43.97 Q4 '19: -9.01 Q1 '20: 7.27 Q2 '20: 21.94 Q3 '20: 23.32 Q4 '20: -1.53 Q1 '21: -1.25 Q2 '21: -1.12 Q3 '21: -0.77 Q4 '21: -88.21 Q1 '22: -111.03 Q2 '22: -119.49 Q3 '22: -128.05 Q4 '22: -40.26 Q1 '23: -19.55 Q2 '23: -52.13 Q3 '23: -65.80 Q4 '23: -2611.92 Q1 '24: -2696.65 Q2 '24: -2657.96 Q3 '24: -2661.75 Q4 '24: -130.69 Q1 '25: -628.02 Q2 '25: -984.30 Q3 '25: -964.29 Q4 '25: -22.97 Q1 '26: 547.88 Q2 '26: 891.12 Q2 '16 Q3 '17 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.